1B940F72-3C90-43C4-9267-185F21D10AC9
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 4.92772667542707
- age_years
- 83
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.697
- G2M_CHECKPOINT+0.642
- MYC_TARGETS_V1+0.642
- MYC_TARGETS_V2+0.563
- MTORC1_SIGNALING+0.549
- UNFOLDED_PROTEIN_RESPONSE+0.508
- DNA_REPAIR+0.488
- HYPOXIA+0.455
- TNFA_SIGNALING_VIA_NFKB+0.434
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.425
Top 10 suppressed
- KRAS_SIGNALING_DN-0.408
- MYOGENESIS-0.212
- BILE_ACID_METABOLISM-0.195
- ESTROGEN_RESPONSE_EARLY-0.064
- PANCREAS_BETA_CELLS-0.056
- HEME_METABOLISM-0.049
- ESTROGEN_RESPONSE_LATE-0.035
- XENOBIOTIC_METABOLISM-0.029
- APICAL_SURFACE-0.024
- SPERMATOGENESIS-0.012
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.971 |
| 2 | SRR934981 | — | — | 0.964 |
| 3 | SRR934835 | — | — | 0.961 |
| 4 | B27956E8-3374-4720-9F80-7CE6FE7C7690 | — | — | 0.959 |
| 5 | E317AD4C-E877-499A-B108-2F39A40D1682 | — | — | 0.957 |
| 6 | EB8F7B74-694A-4F9F-9C0B-F04006033CA4 | — | — | 0.956 |
| 7 | SRR934730 | — | — | 0.955 |
| 8 | SRR934839 | — | — | 0.955 |
| 9 | 769432C5-4BFD-4689-8F43-467010292448 | — | — | 0.955 |
| 10 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.951 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.697 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.642 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.642 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.563 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.549 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.508 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.488 | Idelalisib | — uncovered |
| HYPOXIA | 0.455 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.434 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.425 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.407 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.399 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.387 | Idelalisib | — uncovered |
| APOPTOSIS | 0.380 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.378 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.377 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.370 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.343 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.307 | Inavolisib | — uncovered |